Loading page
Loading page
Loading substance route
High individual variability reported; some users experience strong effects at light doses while others require moderate-to-strong doses for comparable intensity.
These combinations are considered extremely harmful and should always be avoided. Reactions to these drugs taken in combination are highly unpredictable and have a potential to cause death.
There is considerable risk of physical harm when taking these combinations, they should be avoided where possible.
These combinations are not usually physically harmful, but may produce undesirable effects, such as physical discomfort or overstimulation. Extreme use may cause physical health issues. Synergistic effects may be unpredictable. Care should be taken when choosing to use this combination.
2C-B-FLY is not habit-forming, and the desire to use it can actually decrease with use. It is most often self-regulating.
The exact toxic dose is unknown. The toxicity and long-term health effects of recreational 2C-B-FLY have not been studied in any scientific context. Two deaths in October 2009, initially attributed to 2C-B-FLY, were later determined to be caused by mislabeled Bromo-DragonFLY, which is active in micrograms rather than milligrams.
2C-B-FLY was first described in the scientific literature in 1995 by Aaron Phillip Monte and David E. Nichols along with colleagues at Purdue University. Monte, a Professor of Chemistry at the University of Wisconsin-La Crosse, synthesized this novel compound as part of research into the
Controlled under the Neue-Psychoaktive-Substanzen-Gesetz (New Psychoactive Substances Act). Possession, production, and sale are prohibited.
Listed in the government decree on psychoactive substances banned from the consumer market.
Listed as a Schedule I controlled substance. Possession, production, sale, and purchase are illegal.
Not explicitly scheduled under Polish drug law. However, as a derivative of 2,5-dimethoxyphenethylamine, it could potentially be classified as a Group II-P substance under analogue provisions.
Legal status remains unclear. The compound's structural classification under Verzeichnis E point 130 is contested, as it does not clearly fit the definition of an alkyl, alkoxy, alkylenedioxy, or halide derivative of phenethylamine due to its fused ring system.
Controlled under the Psychoactive Substances Act 2016, which came into effect on May 26, 2016. Production, supply, and importation are criminal offenses. The compound was legally available on the open market prior to this blanket ban.
Classified as a controlled substance under Schedule III of the Controlled Drugs and Substances Act as of October 31, 2016. Scheduled as a derivative of 2,5-dimethoxyphenethylamine.
Regulated under the Neue-psychoaktive-Stoffe-Gesetz (New Psychoactive Substances Act) since November 26, 2016. Production and importation with intent to distribute, administration to others, and trading are criminally punishable. Possession is prohibited but carries no penalty.
Currently available as a research chemical when not sold for human consumption. However, pending legislation on New Psychoactive Substances may result in future scheduling.
Controlled substance as of April 2018. Possession, sale, purchase, and use are prohibited under Swedish narcotics legislation.
Classified as a controlled drug. Possession, production, supply, and importation are prohibited.
Not specifically scheduled or controlled under federal law. However, the Federal Analogue Act may apply if the substance is sold or possessed with intent for human consumption, given its structural and pharmacological similarity to the Schedule I substance 2C-B.
13 sources cited
